Jane Street Group LLC decreased its stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Free Report) by 50.1% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 27,842 shares of the company’s stock after selling 28,006 shares during the quarter. Jane Street Group LLC’s holdings in Phathom Pharmaceuticals were worth $503,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently modified their holdings of the company. Jennison Associates LLC boosted its holdings in Phathom Pharmaceuticals by 112.7% in the third quarter. Jennison Associates LLC now owns 5,866,389 shares of the company’s stock valued at $106,064,000 after purchasing an additional 3,108,810 shares during the last quarter. FMR LLC boosted its holdings in Phathom Pharmaceuticals by 49,000.7% in the third quarter. FMR LLC now owns 1,304,114 shares of the company’s stock valued at $23,578,000 after purchasing an additional 1,301,458 shares during the last quarter. Checkpoint Capital L.P. boosted its holdings in Phathom Pharmaceuticals by 71.9% in the third quarter. Checkpoint Capital L.P. now owns 1,504,307 shares of the company’s stock valued at $27,198,000 after purchasing an additional 629,307 shares during the last quarter. Portolan Capital Management LLC boosted its holdings in Phathom Pharmaceuticals by 50.4% in the third quarter. Portolan Capital Management LLC now owns 1,699,918 shares of the company’s stock valued at $30,735,000 after purchasing an additional 569,829 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in Phathom Pharmaceuticals in the third quarter valued at about $7,952,000. Hedge funds and other institutional investors own 99.01% of the company’s stock.
Insider Transactions at Phathom Pharmaceuticals
In related news, Director Frank Karbe purchased 12,500 shares of the company’s stock in a transaction dated Friday, December 13th. The shares were acquired at an average cost of $7.93 per share, for a total transaction of $99,125.00. Following the transaction, the director now owns 57,000 shares of the company’s stock, valued at $452,010. This trade represents a 28.09 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 24.10% of the company’s stock.
Wall Street Analysts Forecast Growth
Read Our Latest Report on PHAT
Phathom Pharmaceuticals Trading Up 5.6 %
Shares of Phathom Pharmaceuticals stock opened at $7.74 on Monday. The business’s 50 day simple moving average is $10.47 and its 200-day simple moving average is $12.88. The stock has a market capitalization of $529.24 million, a price-to-earnings ratio of -1.36 and a beta of 0.56. Phathom Pharmaceuticals, Inc. has a twelve month low of $6.07 and a twelve month high of $19.71.
Phathom Pharmaceuticals Profile
Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
Further Reading
- Five stocks we like better than Phathom Pharmaceuticals
- Bank Stocks – Best Bank Stocks to Invest In
- Cold Front, Hot Stocks: Diesel Prices Propel Energy Leaders
- What Are the U.K. Market Holidays? How to Invest and Trade
- Sustainable and Successful: 3 Climate ETFs Beating the Market
- Canadian Penny Stocks: Can They Make You Rich?
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
Want to see what other hedge funds are holding PHAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Free Report).
Receive News & Ratings for Phathom Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phathom Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.